Year: 2025

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, today reported financial results for the second quarter ended June 30, 2025, and provided a...

LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.46 per share and net income of $0.41 per share for the quarter ended June 30, 2025. Second quarter net investment income includes the impact of one-time accelerated amortization of $0.02 per share related to deferred financing costs. Net asset value (NAV) per share was $19.55 at June 30, 2025. Dividend DeclarationsThe Company announced that its Board of Directors (the “Board”) declared a third quarter 2025 regular cash dividend of $0.42 per share to stockholders of record as of September 30, 2025, payable on October 15, 2025. Additionally, the third and final previously announced $0.05 per share special dividend will be paid on September 15, 2025 to stockholders of record...

All dollar amounts are in USD unless otherwise indicated and abbreviation “M” means million. VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX/ASX: ORE, OTCQX: ORZCF) (“Orezone” or “Company”) is pleased to report its operational and financial results for the three and six months ended June 30, 2025. The Company will host a conference call and webcast today at 2:00pm PT / 5:00pm ET (August 14, 7:00am AEST) to discuss the results. Details to join the conference call and webcast are provided at the end of this release. Second Quarter 2025 HighlightsGold production of 27,548 ounces at an AISC of $1,830 per ounce sold Revenue of $94.5M from the sale of 28,265 ounces at an average realized price of $3,338 per ounce Adjusted EBITDA of $45.5M, Adjusted Earnings attributable to Orezone shareholders...

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity — ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketable securities of $147.6 million as of June 30, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass., Aug. 13, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing...

Company remains on track for its goal of achieving platform adjusted EBITDA profitability in the second half of 2025 SCOTTSDALE, Ariz., Aug. 13, 2025 (GLOBE NEWSWIRE) — Caliber (NASDAQ: CWD; “CaliberCos Inc.”), a real estate investor, developer, and asset manager, today reported results for the second quarter ended on June 30, 2025. Second Quarter 2025 Platform Financial Highlights (compared to Second Quarter 2024)Platform revenue of $4.1 million, compared to $4.2 millionAsset management revenue of $4.1 million drove the stated results No significant performance allocations were earned, compared to prior periodPlatform net loss of $4.9 million, or $3.87 per diluted share, compared to Platform net loss of $4.6 million, or $4.25 per diluted share Platform Adjusted EBITDA loss of $0.1 million, compared to Platform Adjusted...

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for pipeline assets Alvotech listed on Nasdaq Stockholm Market Conference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT)REYKJAVIK, Iceland, August 13, 2025 – Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT). “The strong results from the first...

Strong performance driven by over 200% growth in product revenues year-on-yearBest quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for pipeline assetsAlvotech listed on Nasdaq Stockholm MarketConference call and live webcast on Thursday August 14, 2025, 8:00 am ET (12:00pm GMT)REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on August 14, 2025, at 8:00 am ET (12:00 pm GMT). “The strong...

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026WASHINGTON, Aug. 13, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today its financial results for the second quarter of 2025, ended June 30, 2025. While net product revenues declined compared to Q2 2024 due to a now resolved supply chain disruption, the Company reported an increase in profitability, largely attributed to cash-pay patients using KODATEF® (tafenoquine) 16-count boxes which were imported with U.S. Food and Drug Administration (FDA) consent to help mitigate a temporary...

MINNETONKA, Minn., Aug. 13, 2025 (GLOBE NEWSWIRE) — Table Trac, Inc. (OTCQX: TBTC), a developer and provider of casino information and management systems that automate and monitor the operations of casinos, announced financial results for the three and six months ending June 30, 2025. The 10-Q can be found @ http://www.sec.gov Second Quarter 2025 HighlightsThe Company installed one system at a new customer location. The Company had two customers with system contracts in backlog as of June 30, 2025. The company anticipates that these contracts will be installed during the third quarter of 2025. As of the filing date of this report, the Company signed one new contract.Second Quarter 2025 Financial ResultsMaintenance revenues increased 19.4% from $1.32M in 2024 to $1.58M in 2025.The following table provides a reconciliation...

CHICO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the second quarter ended June 29, 2025 and updated its Adjusted EBITDA financial outlook for the third quarter ending September 28, 2025 and its capital expenditure outlook for the year ending December 28, 2025. Crystal Landsem, CEO and Interim CFO of Lulus, said: “In the second quarter, we saw meaningful sequential improvement in our quarterly year-over-year net revenue comparison, and we continued to see positive sales momentum in occasion dresses, led by our bridesmaid category. This performance was offset by continued softness in casual wear and footwear, which we are actively repositioning to better align with our strengths in event attire. We remain encouraged...